Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varicella-zoster virus mRNA vaccine
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Varicella-zoster virus mRNA vaccine is an investigational vaccine candidate developed by Walvax Biotechnology utilizing messenger RNA (mRNA) technology. It is designed to prevent infections caused by the varicella-zoster virus (VZV), which is responsible for both varicella (chickenpox) and herpes zoster (shingles). The vaccine works by introducing mRNA that encodes for a specific VZV antigen into the body, prompting host cells to produce the viral protein and subsequently triggering a robust immune response, including the production of neutralizing antibodies and the activation of T-cells. This approach aims to provide long-lasting protection against VZV reactivation and associated complications. As of early 2024, the vaccine is in Phase 1 clinical trials to assess its safety and immunogenicity profile.
- Other names
- VZV mRNA vaccineWalvax VZV mRNA vaccine
Beyond the preview
Go deeper on Varicella-zoster virus mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Varicella-zoster virus mRNA vaccine.